Catalog No.
Product Name
Application
Product Information
Citations
-
Mucofluidifying Agent
trans-Sobrerol is a potent mucofluidifying agent that acts primarily to enhance hippocampal cholinergic signaling. It exhibits significant anti-amnesic effects, demonstrating properties that counteract tau hyperphosphorylation and Aβ synthesis. Furthermore, trans-Sobrerol effectively alleviates memory impairment induced by scopolamine, making it a valuable tool for investigating mechanisms underlying Alzheimer's disease. -
Aβ Aggregation Inhibitor
AY1511 is an amyloid β (Aβ) aggregation inhibitor that demonstrates low cytotoxicity. This compound is utilized in research focusing on neurodegenerative diseases, particularly Alzheimer's disease, by inhibiting the aggregation of Aβ peptides. AY1511 serves as a valuable tool for studying the mechanisms of amyloid pathology and the development of potential therapeutic strategies. -
Aβ40/tau Aggregation Inhibitor
Tau/Aβ40 aggregation-IN-1 is a potent inhibitor of tau and Aβ40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively. This compound is of significant interest in Alzheimer's disease research, as it targets the pathological aggregation of tau protein and amyloid-beta peptides. Its effectiveness in modulating these protein interactions makes it a valuable tool for studying neurodegenerative mechanisms and potential therapeutic interventions. -
paeonol derivative
6′-Methyl paeonol is a derivative of paeonol that primarily targets neuronal pathways. It demonstrates inhibitory effects on abnormal depolarizations and reduces Amyloid β-induced ERK phosphorylation. This compound shows promise for alleviating symptoms associated with Alzheimer's Disease, making it a valuable tool for research in neurodegenerative disorders. -
Amyloid-β
β-Amyloid (22-40) is a peptide fragment derived from the amyloid precursor protein, primarily targeting amyloid-β. This fragment is pivotal in the study of amyloid aggregation and plaque formation associated with Alzheimer's disease. Its application in research includes elucidating amyloid pathophysiology and screening potential therapeutic compounds for neurodegenerative disorders. -
Amyloid β Inhibitor
Aβ-IN-4 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. It effectively halts the aggregation process of Aβ42, which is central to the pathogenesis of Alzheimer’s disease. However, Aβ-IN-4 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it modify the aggregation state of Aβ42 into a non-toxic form. This compound is valuable for research investigating Aβ-related mechanisms and the development of Alzheimer’s therapeutics. -
Amyloid-β
β-Amyloid (18-28) is a peptide fragment primarily targeting amyloid-β, a protein implicated in the pathogenesis of Alzheimer's disease. This fragment plays a key role in studying amyloid aggregation and neurotoxicity associated with Alzheimer's pathology. It serves as a valuable tool in research aimed at understanding the mechanisms of amyloid toxicity and developing potential therapeutic strategies. -
Neuroprotective Agent
GLY-230 is an orally active neuroprotective agent that inhibits nonenzymatic glycation and decreases glycated albumin levels. This compound has been shown to lower brain Aβ42 levels, highlighting its potential in mitigating neurodegenerative processes. GLY-230 is suitable for research applications related to metabolic and neurological diseases, including diabetic renal dysfunction. -
Amyloid-β
β-Amyloid (4-10) is a key epitope that interacts specifically with the polyclonal anti-Aβ(1-42) antibody, targeting the amyloid-β peptide. This compound exhibits significant biological activity by reducing amyloid deposition in transgenic mouse models of Alzheimer's disease. It serves as a valuable tool for investigating amyloid pathology and potential therapeutic strategies in neurodegenerative research. -
Anti-Alzheimer Agent
SV5 is a potent anti-Alzheimer agent that primarily targets and protects neuronal cells. It significantly reduces Aβ1-42-induced cytotoxicity in SHSY-5Y cell lines, demonstrating its effectiveness in neuroprotection. Additionally, SV5 exhibits moderate antioxidant properties and maintains high stability in human plasma, contributing to its favorable pharmacological profile for potential therapeutic applications in Alzheimer's disease research. -
Amyloid-β Inhibitor
AZ4800 is an amyloid-β inhibitor that targets the processing of amyloid precursor protein. It effectively reduces Aβ42 levels, demonstrating additive lowering activity both in vitro and in vivo. This compound is valuable for research focusing on Alzheimer's disease and related neurodegenerative disorders. -
Amyloid β
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) targets amyloid β and consists of the 36-42 fragment of the amyloid β-protein. This peptide is critical in the study of Alzheimer's disease, as it is a major component of amyloid plaques that contribute to neurodegeneration. Research has shown that β-amyloid oligomers (Aβos) are instrumental in inducing neuronal damage and cognitive decline, making this fragment an important tool for investigating the pathophysiology of Alzheimer's disease and potential therapeutic interventions. -
Alpha-Synuclein Binder
α-Synuclein aggregate binder 2 is a specific binder for alpha-synuclein, exhibiting a binding affinity characterized by a Ki of 1.6 nM. This compound demonstrates a weaker interaction with β-amyloid aggregates, with a Ki of 295 nM. It is valuable in research applications focused on Parkinson's disease, serving as a tracer to investigate alpha-synuclein aggregation and its implications in neurodegenerative disorders. -
Aβ Deposits Label
p-HTAA is a pentamer hydrogen thiophene acetic acid that specifically labels amyloid beta (Aβ) deposits in the living brain of mice. It serves as a valuable tool for studying Alzheimer's disease by facilitating the visualization of Aβ pathology in real-time. Researchers can utilize p-HTAA for in vivo imaging and studies focusing on the progression and therapeutic interventions of neurodegenerative disorders. -
Neuroprotective Agent
JBPOS-0101 is a phenyl carbamate compound that acts as a neuroprotective agent. This compound has demonstrated neuroprotective and antiepileptic effects, specifically attenuating the accumulation of amyloid-beta (Aβ) in the brains of 5XFAD mouse models. Additionally, JBPOS-0101 has been shown to rescue deficits in learning and memory, making it a valuable tool for research into neurological diseases, including Alzheimer's disease. -
BACE1 Inhibitor
TAK-070 hydrochloride hydrate is a noncompetitive inhibitor of BACE1 with an IC50 value of 3.15 μM. This compound is actively researched for its potential therapeutic effects in Alzheimer's disease, demonstrating the ability to reduce brain levels of soluble Aβ. Additionally, TAK-070 hydrochloride hydrate has shown promise in ameliorating cognitive impairments in preclinical models of Alzheimer's disease, making it a valuable tool for studying neurodegenerative disorders. -
Amyloid Subunit
ABri is a 34-amino acid amyloid subunit characterized by N- and C-terminal heterogeneity and a unique sequence lacking glycine, methionine, proline, aspartic acid, tryptophan, tyrosine, and glutamine, with pyroglutamate at the N-terminus. This peptide is significant for studying amyloid-related pathologies, particularly in the context of cerebral hemorrhages, ischemic infarction, and Alzheimer’s disease. It serves as a valuable reagent for researchers investigating amyloid formation and associated neurodegenerative processes. -
Sigma Receptor Ligand
Caprospinol is a potent σ-1 receptor ligand that exhibits neuroprotective properties through multiple mechanisms. It effectively binds to β-amyloid protein (Aβ(42)), interacts with the mitochondrial respiratory chain, and facilitates the clearance of Aβ(42) monomers. Caprospinol is capable of crossing the blood-brain barrier, thereby showing promise in restoring cognitive function and inhibiting the progression of Alzheimer's disease. Its diverse biological activities make it a valuable tool for research in neurodegenerative disorders. -
Amyloid-β Oligomerization Inhibitor
RI-OR2 is an amyloid-β (Aβ) oligomerization inhibitor that functions as a retro-inverso peptide. It has been shown to bind effectively to immobilized β-Amyloid (1-42) monomers and fibrils, demonstrating an apparent dissociation constant (Kd) of 9-12 μM. Additionally, RI-OR2 inhibits the extension of Aβ(1-42) fibrils, making it a valuable tool for research into Alzheimer’s disease and the mechanisms of amyloid pathology. -
Neuroprotective Agent
Heishuixiecaoline A is a germacrane-type sesquiterpenoid that acts as a neuroprotective agent. This compound exhibits a protective effect against neurotoxicity in PC12 cells induced by amyloid beta peptide 25-35 (Aβ25-35). Its potential applications include neurobiology research and studies focused on neurodegenerative diseases. -
Anti-Aβ Agent
Anti-Aβ Agent 1A is a potent inhibitor of amyloid-β aggregation, contributing to the modulation of neuroinflammatory responses. This compound significantly reduces LPS-induced secretion of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, while also decreasing H2O2-induced apoptosis in SH-SY5Y cells via a mitochondrial pathway. With its combined antioxidant, anti-inflammatory, and neuroprotective properties, Anti-Aβ Agent 1A is a valuable tool for research focused on Alzheimer’s disease and related neurodegenerative disorders. -
Aβ-Fibrinogen Inhibitor
RU-505 is a potent inhibitor of the β-amyloid (Aβ) and fibrinogen interaction, demonstrating IC50 values of 5.00 μM and 2.72 μM in fluorescence polarization and AlphaLISA assays, respectively. This compound exhibits high permeability across the blood-brain barrier (BBB), making it a valuable tool in targeting cerebral amyloid angiopathy (CAA). RU-505 is applicable in research studies focused on Alzheimer's disease (AD) pathogenesis and potential therapeutic interventions. -
Oligothiophene
q-FTAA is an oligothiophene that specifically targets the X-34 binding site on amyloid-beta (Aβ) fibrils. This compound demonstrates significant capability in the detection and characterization of Aβ aggregates, making it valuable for Alzheimer's disease research. Its unique binding properties facilitate studies related to peptide structure and aggregation dynamics, offering insights into amyloid pathology and potential therapeutic strategies. -
Neuroprotective Compound
RS-0466 is a neuroprotective compound that inhibits β-amyloid-induced cytotoxicity. This compound demonstrates significant protective effects against neurodegeneration associated with Alzheimer's disease. It serves as a valuable tool for investigating therapeutic strategies aimed at enhancing neuronal survival and function in neurodegenerative disorders. -
Gamma-Secretase Modulator
γ-Secretase modulator 13 is a gamma-secretase modulator that inhibits the production of the aggregated amyloid β-peptide Aβ42, exhibiting an IC50 value of 163 nM. This compound is valuable for research in Alzheimer's disease, facilitating investigations into amyloidogenic processes and potential therapeutic interventions. Its specific modulation of γ-secretase activity positions it as a significant tool for studying the mechanisms underlying neurodegenerative disorders. -
Amyloid-β
2002-H20 is an inhibitor of amyloid-β (Aβ42) that functions by binding to the peptide to reduce its cytotoxic effects associated with Alzheimer's disease. This compound promotes fibril formation and may enhance Aβ aggregation, thereby protecting cells from Aβ-induced toxicity. 2002-H20 is a valuable tool for screening compounds that mitigate Aβ toxicity and holds potential as an inhibitory lead in Alzheimer's research. -
Gamma-Secretase Modulator
Gamma-secretase modulator 5 is a selective gamma-secretase modulator that effectively inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 60 nM. This compound demonstrates the ability to penetrate the blood-brain barrier, making it a valuable tool in the investigation of Alzheimer's disease mechanisms. It is suitable for research applications aimed at understanding the role of gamma-secretase in neurodegenerative disorders. -
Aβ Tracer
BIBD-124 is a selective amyloid beta (Aβ) tracer, exhibiting a binding affinity with an IC50 value of 9.51 nM. This compound is utilized as a radiotracer for imaging Aβ plaques, facilitating research into the pathophysiology of neurodegenerative diseases such as Alzheimer's disease. Its high specificity and potency make it a valuable tool for studying amyloid deposition and for the development of potential therapeutic interventions. -
biotinylated β-Amyloid (1-42), human (TFA) (HY-P1363)
Biotinyl-Ahx-Amyloid β-Protein (1-42) is a biotinylated form of the human β-Amyloid (1-42) peptide. This compound is designed for use in various biological assays and research applications that investigate Alzheimer's disease pathology and amyloid plaque formation. Its biotinylation facilitates the study of protein interactions and the development of diagnostic tools, making it a valuable reagent for neurodegeneration research. -
BACE1 Inhibitor
TAK-070 Free base is a noncompetitive inhibitor of BACE1 with an IC50 of 3.15 μM. This compound exhibits significant potential in Alzheimer's disease research by reducing brain levels of soluble Aβ and ameliorating cognitive deficits in AD models. Its ability to modulate amyloid-beta processing makes it a valuable tool for investigating therapeutic strategies targeting Alzheimer's pathology. -
Beta-Sheet Breaker
RS-0406 is a beta-sheet breaker that targets Amyloid-β. It effectively inhibits the fibrillogenesis of Aβ(1-42) and offers neuroprotective effects against Aβ(1-42)-induced cytotoxicity in primary hippocampal neurons. This compound is suitable for research applications in neurological diseases, particularly Alzheimer's disease. -
Aβ Fragment
β Amyloid (1-39) is a key fragment of amyloid-beta, primarily involved in Alzheimer's disease pathology. This peptide plays a crucial role in the aggregation of amyloid plaques and is essential for studies on neurodegeneration and synaptic dysfunction. It serves as an important tool for research applications focusing on the mechanisms of Alzheimer's disease and the development of potential therapeutic strategies. -
Aβ Inhibitor
TPI-1917-49 is an Aβ inhibitor that effectively crosses the blood-brain barrier to decrease levels of amyloid beta (Aβ) peptide segments. By promoting the non-amyloidogenic pathway of amyloid precursor protein (APP), TPI-1917-49 enhances the generation of soluble APPα through α-secretase activity, thereby reducing amyloid plaque formation in murine models. This compound is suitable for research investigating Alzheimer's disease and its related pathologies. -
Amyloid-β
Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide targeting amyloid-β, which is implicated in the pathogenesis of Alzheimer’s disease. This compound features a potential copper(II) binding site, making it valuable for studies investigating metal ion interactions in neurodegenerative disorders. It is suitable for research aimed at understanding the molecular mechanisms of Alzheimer's disease and developing therapeutic strategies. -
reverse version of β-Amyloid (25-35) (HY-P0128)
β-Amyloid (35-25) is a reverse peptide of β-Amyloid (25-35), designed to study the implications of altered peptide sequences in amyloid pathology. It exhibits similar biological activity, making it relevant for research into Alzheimer's disease and other neurodegenerative disorders. This peptide can facilitate investigations into peptide aggregation, neurotoxicity, and potential therapeutic interventions by providing insights into the mechanisms of amyloid plaque formation and stability. -
Aβ Fragment
Amyloid β-Protein (1-6) is an Aβ fragment that plays a critical role in Alzheimer's disease research. This peptide has been shown to aggregate and form fibrils, contributing to plaque formation in the brain, which is a hallmark of neurodegenerative disorders. It serves as an important tool for studying amyloid pathology, understanding protein misfolding, and exploring potential therapeutic targets in Alzheimer's disease and related conditions. -
Aβ1-42 Aggregation Inhibitor
Aβ-IN-1 is an Aβ1-42 aggregation inhibitor that effectively prevents the aggregation of Aβ1-42 peptides in vitro. By delaying the exponential growth phase and reducing the steady-state quantity of fibrils, Aβ-IN-1 serves as a valuable tool for studying conformational disorders. This reagent is particularly relevant for research focused on Alzheimer's disease and other amyloid-related pathologies. -
Aβ Fragment
(Glu20)-Amyloid β-Protein (1-42) is a modified variant of amyloid β-protein designed to reduce the aggregation propensity associated with Aβ42. The Glu20 mutation results in a slower fibrillization process, thereby preventing the accumulation of this peptide. This compound holds significant relevance for research into the pathophysiology of Alzheimer's disease, where amyloid β-protein is a key component of amyloid deposits in both vascular and parenchymal tissues. -
TOP Substrate
Mca-SEVKMDAEFRK(Dnp)RR-NH2 is a substrate specifically designed for thimet oligopeptidase (TOP), featuring the beta-secretase cleavage site of the wild-type amyloid precursor protein (APP). This compound plays a crucial role in elucidating the processing of APP and the pathways leading to Alzheimer's disease. It serves as a valuable tool for researchers investigating amyloid pathology and related neurodegenerative processes. -
Amyloid-β
β-Amyloid (11-22) is a peptide fragment derived from the amyloid-β protein, targeting amyloid-β aggregation and deposition. This compound plays a crucial role in neurodegenerative research, particularly in the study of Alzheimer's disease pathology. Its ability to influence amyloid formation makes it a valuable tool for investigating amyloid-related mechanisms and potential therapeutic interventions in cognitive decline. -
Amyloid-β Inhibitor
BSBM6 is an amyloid-β (Aβ) inhibitor that effectively prevents Aβ aggregation and modulates its formation. This compound has been shown to reduce soluble oligomers, thereby potentially aiding in the treatment of neurodegenerative diseases associated with amyloid pathology. BSBM6 serves as a valuable tool for researchers studying Aβ dynamics and for the design of novel aggregation-modulating ligands. -
Negative Control
β Amyloid (1-42) (scrambled) serves as a negative control for β-Amyloid (1-42), a peptide associated with Alzheimer's disease progression. The scrambled sequence ensures that any observed biological effects in experimental settings can be attributed specifically to the active form of β-Amyloid (1-42). This reagent is useful for validating experimental results in studies focused on amyloid pathology and neurodegenerative research. -
Aβ42 Inhibitor
CHF5022 is an inhibitor of Aβ42 secretion, exhibiting an IC50 value of 92 μM. In addition to its primary activity, CHF5022 demonstrates modest inhibition of Aβ40 at non-cytotoxic concentrations, achieving a reduction of approximately 22.2% at 100 μM. This compound is valuable for research into Alzheimer's disease and the mechanisms of amyloid-beta peptide regulation. -
Amyloid-β42 Inhibitor
Kayaflavone is a biflavonoid of the amentoflavone type known for its inhibitory activity against amyloid-β42 cytotoxicity in PC-12 cells, exhibiting an EC50 value of 5.29 μM. This compound holds potential for research applications in Alzheimer’s disease, contributing to the understanding of amyloid-related neurotoxicity and its implications in neurodegenerative processes. -
Aβ Fragment
β-Amyloid (1-8) is an Aβ fragment that functions as a crucial component in the study of Alzheimer's disease. This peptide is instrumental in investigating the aggregation and toxicity of amyloid-beta, which are key features of neurodegeneration. It serves as a valuable tool for researchers exploring potential therapeutic strategies and the underlying mechanisms of amyloid pathology. -
Aβ Aggregation Stimulator
Aβ aggregation modulator-1 is a stimulator of amyloid-β (Aβ) fibrillogenesis, targeting the stabilization of β-sheet-rich protofibrils and fibrils by binding to hydrophobic residues in Aβ peptides. This compound accelerates Aβ polymerization while decreasing the concentration of small, toxic Aβ oligomers in heterogeneous aggregation reactions. Additionally, Aβ aggregation modulator-1 mitigates the inhibition of long-term potentiation (LTP) caused by Aβ oligomers in hippocampal brain slices. This reagent is valuable for researching Alzheimer's disease (AD) and its underlying mechanisms. -
RAGE Inhibitor
Azeliragon dihydrochloride is a selective inhibitor of the receptor for advanced glycation end products (RAGE). This compound demonstrates the ability to cross the blood-brain barrier and has been investigated for its potential to mitigate disease progression in patients with mild Alzheimer's disease. Its mechanism of action involves reducing neuroinflammation and promoting neuronal health, making it a promising candidate for research focused on Alzheimer's disease therapeutics. -
APP Modulator
APP Modulator-1 is a compound that specifically targets the amyloid precursor protein (APP) to influence its processing and thereby modulate the production of amyloid-beta peptides. This activity suggests potential applications in Alzheimer's disease research, particularly in understanding the mechanisms of amyloid plaque formation. APP Modulator-1 is suitable for studies aimed at elucidating the role of APP in neurodegenerative disorders and developing therapeutic strategies for related conditions. -
Aβ Aggregation Inhibitor
TDI-2760 is an Aβ aggregation inhibitor with an IC50 of 1.67 μM, specifically targeting the aggregation of amyloid-beta peptides. This compound effectively inhibits Aβ-fibrinogen interactions and modulates contact system activation induced by Aβ42. TDI-2760 is suitable for research focused on Alzheimer's disease, particularly in the study of vascular abnormalities associated with Aβ aggregation. -
Buffering Agent
HEPPS is a buffering agent with an effective pH range of 7.3 to 8.7. This compound has demonstrated the ability to reduce amyloid beta (Aβ) aggregate-induced memory deficits and improve cognitive functions in murine models. HEPPS is orally active and capable of crossing the blood-brain barrier, making it valuable for neuroscience research.
